Literature DB >> 2909558

Endomyocardial biopsy in hemochromatosis: clinicopathologic correlates in six cases.

L J Olson1, W D Edwards, D R Holmes, F A Miller, L A Nordstrom, W P Baldus.   

Abstract

Clinical and pathologic features of cardiac hemochromatosis diagnosed by endomyocardial biopsy in six men, aged 32 to 75 years (mean 52), are described. Echocardiography demonstrated left ventricular enlargement and marked global systolic dysfunction in five. Cardiac catheterization demonstrated normal coronary arteries, increased left ventricular end-diastolic pressure and decreased left ventricular systolic function in all five so studied. Stainable iron was present in all endomyocardial biopsy specimens from the five patients with decreased left ventricular systolic function. Histologically, iron was detected only within the sarcoplasm, and its extent varied inversely with ventricular function. Thus, cardiac hemochromatosis represents a storage rather than an infiltrative disease. These results indicate that stainable iron is consistently observed in endomyocardial biopsy specimens from patients with impaired left ventricular systolic function. Iron staining is recommended for endomyocardial biopsy specimens from patients with idiopathic cardiac dysfunction.

Entities:  

Mesh:

Year:  1989        PMID: 2909558     DOI: 10.1016/0735-1097(89)90558-5

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  18 in total

1.  Improved R2* measurements in myocardial iron overload.

Authors:  Nilesh R Ghugre; Cathleen M Enriquez; Thomas D Coates; Marvin D Nelson; John C Wood
Journal:  J Magn Reson Imaging       Date:  2006-01       Impact factor: 4.813

2.  Diagnostic endomyocardial biopsy--still useful after all these years.

Authors:  John P Veinot
Journal:  Can J Cardiol       Date:  2009-02       Impact factor: 5.223

3.  On T2* magnetic resonance and cardiac iron.

Authors:  John-Paul Carpenter; Taigang He; Paul Kirk; Michael Roughton; Lisa J Anderson; Sofia V de Noronha; Mary N Sheppard; John B Porter; J Malcolm Walker; John C Wood; Renzo Galanello; Gianluca Forni; Gualtiero Catani; Gildo Matta; Suthat Fucharoen; Adam Fleming; Michael J House; Greg Black; David N Firmin; Timothy G St Pierre; Dudley J Pennell
Journal:  Circulation       Date:  2011-03-28       Impact factor: 29.690

4.  Syncope and inducible ventricular fibrillation in a woman with hemochromatosis.

Authors:  J S Strobel; A R Fuisz; A E Epstein; V J Plumb
Journal:  J Interv Card Electrophysiol       Date:  1999-10       Impact factor: 1.900

Review 5.  Overview of hemochromatosis.

Authors:  L H Smith
Journal:  West J Med       Date:  1990-09

Review 6.  Transplantation in patients with iron overload: is there a place for magnetic resonance imaging? : Transplantation in iron overload.

Authors:  Sophie Mavrogeni; Genovefa Kolovou; Boris Bigalke; Angelos Rigopoulos; Michel Noutsias; Stamatis Adamopoulos
Journal:  Heart Fail Rev       Date:  2018-03       Impact factor: 4.214

Review 7.  Iron overload cardiomyopathy: better understanding of an increasing disorder.

Authors:  Pradeep Gujja; Douglas R Rosing; Dorothy J Tripodi; Yukitaka Shizukuda
Journal:  J Am Coll Cardiol       Date:  2010-09-21       Impact factor: 24.094

8.  Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy.

Authors:  John C Wood; Maya Otto-Duessel; Michelle Aguilar; Hanspeter Nick; Marvin D Nelson; Thomas D Coates; Harvey Pollack; Rex Moats
Journal:  Circulation       Date:  2005-07-18       Impact factor: 29.690

9.  Cardiac iron overload in thalassemic patients: an endomyocardial biopsy study.

Authors:  T Lombardo; C Tamburino; G Bartoloni; M L Morrone; V Frontini; F Italia; S Cordaro; A Privitera; V Calvi
Journal:  Ann Hematol       Date:  1995-09       Impact factor: 3.673

10.  International survey of T2* cardiovascular magnetic resonance in β-thalassemia major.

Authors:  John-Paul Carpenter; Michael Roughton; Dudley J Pennell
Journal:  Haematologica       Date:  2013-06-28       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.